EUVIMEDEUVIMED entdecken
Crossref

Enhanced Type 1 Interferon Signature in Axial Spondyloarthritis Patients Unresponsive to Secukinumab Treatment

Addison Pacheco iD, Sinead Maguire, Zoya Qaiyum, Michael Tang, Adam Bridger, Melissa Lim, Fataneh Tavasolian, Enoch Yau, Sarah Q Crome, Nigil Haroon iD, Robert D Inman iD

Arthritis & Rheumatology · 2025-01 · 77 (1) · 34-46

DOI: 10.1002/art.42974 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 10.10.2024. Verfasst von Addison Pacheco und 10 weiteren Autor:innen. Beteiligte Einrichtung: Schroeder Arthritis Institute, University Health Network and University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Interferon Type I, Interleukin-17, Axial Spondyloarthritis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Novartis Pharmaceuticals Canada, Arthritis Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Axial spondyloarthritis (axSpA) is an inflammatory disease in which overactive interleukin (IL)‐17A–producing cells are implicated in a central role. Therapeutically, biologics that target IL‐17A, such as secukinumab, have demonstrated improved clinical outcomes. Despite this translational success, there is a gap in understanding why some patients with axSpA do not respond to IL‐17A–blocking therapy. Our study aims to discriminate immune profiles between secukinumab responders (SEC‐R) and nonresponders (SEC‐NR).

Methods

Peripheral blood mononuclear cells were collected from 30 patients with axSpA before and 24 weeks after secukinumab treatment. Frequency of CD4+ subsets were compared between SEC‐R and SEC‐NR using flow cytometry. Mature CD45RO+CD45RA‐CD4+ T cells were fluorescent‐activated cell sorting sorted, and RNA was measured using NanoString analysis.

Results

SEC‐NR had an increased frequency of IL‐17A–producing RORγt+CD4+ T cells compared to healthy controls before secukinumab treatment ( P < 0.01). SEC‐NR had a significant increase of CXCR3+ CD4+ T cells before secukinumab treatment compared to SEC‐R ( P < 0.01). Differentially expressed gene analysis revealed up‐regulation of type 1 interferon (IFN)‐regulated genes in SEC‐NR patients compared to SEC‐R patients after receiving the biologic. SEC‐R patients had an up‐regulated cytotoxic CD4+ T cell gene signature before receiving secukinumab treatment compared to SEC‐NR patients.

Conclusion

The increased frequency of IL‐17A–producing cells in SEC‐NR patients suggests a larger inflammatory burden than SEC‐R patients. With treatment, SEC‐NR patients have a more pronounced type 1 IFN signature than SEC‐R patients, suggesting a mechanism contributing to this larger inflammatory burden. The results point toward more immune heterogeneity in axSpA than has been recognized and highlights the need for precision therapeutics in this disease. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedInterferon Type IInterleukin-17Axial SpondyloarthritisHumansMaleFemaleAdultMiddle AgedCD4-Positive T-LymphocytesLeukocytes, MononuclearAntirheumatic Agents

Substanzen

secukinumabAntibodies, Monoclonal, HumanizedInterferon Type IInterleukin-17IL17A protein, humanAntirheumatic Agents

Autor:innen und Institutionen

  • Schroeder Arthritis Institute, University Health Network and University of Toronto, Toronto, Ontario, Canada.
  • Schroeder Arthritis Institute, University Health Network and Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.
  • Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada.
  • University of Toronto, Ajmera Transplant Centre, University Health Network, and Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.
  • University of Toronto and Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.
  • Schroeder Arthritis Institute, University Health Network, Ajmera Transplant Centre, University Health Network, Toronto Western Hospital, University Health Network, and University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Addison Pacheco, Nigil Haroon, Robert D Inman

Förderung

  • Novartis Pharmaceuticals Canada
  • Arthritis Society

Zitieren

APA

Pacheco, A., Maguire, S., Qaiyum, Z., Tang, M., Bridger, A., Lim, M., Tavasolian, F., Yau, E., Crome, S. Q., Haroon, N., & Inman, R. D. (2025). Enhanced Type 1 Interferon Signature in Axial Spondyloarthritis Patients Unresponsive to Secukinumab Treatment. Arthritis & Rheumatology, 77(1), 34-46. https://doi.org/10.1002/art.42974

Vancouver

Pacheco A, Maguire S, Qaiyum Z, Tang M, Bridger A, Lim M, et al. Enhanced Type 1 Interferon Signature in Axial Spondyloarthritis Patients Unresponsive to Secukinumab Treatment. Arthritis & Rheumatology. 2025;77(1):34-46. doi:10.1002/art.42974

BibTeX
@article{Pacheco2025,
  author = {Pacheco, Addison and Maguire, Sinead and Qaiyum, Zoya and Tang, Michael and Bridger, Adam and Lim, Melissa and Tavasolian, Fataneh and Yau, Enoch and Crome, Sarah Q and Haroon, Nigil and Inman, Robert D},
  title = {Enhanced Type 1 Interferon Signature in Axial Spondyloarthritis Patients Unresponsive to Secukinumab Treatment},
  journal = {Arthritis & Rheumatology},
  year = {2025},
  volume = {77},
  number = {1},
  pages = {34--46},
  doi = {10.1002/art.42974}
}
Kostenlos starten →